Theralase Technologi (TLTFF) 0.5753 $TLTFF
Brian C. Wilson Joins Theralase Medical and Scientific Advisory Board
ACCESSWIRE - Tue Dec 16, 6:07AM CST
Toronto, Ontario / ACCESSWIRE / December 16, 2014 / Theralase Technologies Inc. ("Theralase"

(TLT:TSXV) (TLTFF: OTC Pink(R)) announced today that Brian C. Wilson, PhD has agreed to join the Theralase Medical and Scientific Advisory Board ("MSAB"

.
TLT.VN: 0.630 (-0.010)
University of Toledo Validates University Health Network In-Vitro Data
TheNewswire.ca - Tue Dec 09, 6:05AM CST
(via Thenewswire.ca)
TLT.VN: 0.630 (-0.010)
Dr. Michael A. O'Donnell Joins Theralase Medical and Scientific Advisory Board
ACCESSWIRE - Wed Dec 03, 6:07AM CST
Toronto, Ontario / ACCESSWIRE / December 3, 2014 / Theralase Technologies Inc. ("Theralase"

(TLT:TSXV) (TLTFF: OTC Link(R)) announced today that Michael A. O'Donnell, MD, Professor of Urology, University of Iowa located in Iowa City, Iowa has agreed to join the Theralase Medical and Scientific Advisory Board ("MSAB"

.
TLT.VN: 0.630 (-0.010)
Dr. Ashish M. Kamat Joins Theralase Medical and Scientific Advisory Board
TheNewswire.ca - Tue Dec 02, 10:36AM CST
(via Thenewswire.ca)
TLT.VN: 0.630 (-0.010)
Theralase Releases 3Q2014 Financials
ACCESSWIRE - Fri Nov 28, 7:43AM CST
Toronto, Ontario / ACCESSWIRE / November 28, 2014 / Theralase Technologies Inc. ("Theralase"

(TLT: TSXV) (TLTFF: OTC Link(R)) released its third quarter 2014 financial results today, demonstrating a decrease in revenue for the three month period ended September 30, 2014 of 57% and a decrease in revenue of 15% for the nine month period ended September 30, 2014, while making dramatic progress in both its patented next generation Therapeutic Laser Technology ("TLT"

division and its Photo Dynamic Therapy ("PDT"

anti-cancer division.
TLT.VN: 0.630 (-0.010)
Theralase Releases Annual General Meeting Video
ACCESSWIRE - Tue Nov 25, 6:06AM CST
Toronto, Ontario / ACCESSWIRE / November 25, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTCBB) announced today that it has released a video of the presentations conducted at the Theralase 2013 Annual General Meeting ("AGM"

, held on November 14, 2014. The presentations were conducted by Theralase President and CEO, Roger Dumoulin-White and Dr. Lothar Lilge, Professor in the Department of Medical Biophysics University of Toronto and Senior Scientist, Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network ("UHN"

.
TLT.VN: 0.630 (-0.010)
Theralase Further Validates Anti-Cancer Memory Response
ACCESSWIRE - Mon Nov 17, 9:55AM CST
Toronto, Ontario / ACCESSWIRE / November 17, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTCBB) announced today that in new preclinical research, conducted at Princess Margaret Cancer Centre, University Health Network ("UHN"

, that it has further validated its Photo Dynamic Compound's ("PDCs"

ability to destroy a primary host tumour and even more importantly render the animal immune to a repeated exposure of the same cancer.
TLT.VN: 0.630 (-0.010)
Theralase Presents Latest Research on Destruction of Cancer and Bacteria at International Conference
ACCESSWIRE - Thu Oct 16, 6:09AM CDT
Toronto, Ontario - October 16, 2014 -Theralase Technologies Inc. ("Theralase(R)"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds ("PDCs"

in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014.
TLT.VN: 0.630 (-0.010)
Theralase Partners with SAFC in Manufacture of Anti-Cancer Drugs
ACCESSWIRE - Tue Oct 07, 6:08AM CDT
Toronto, Ontario / ACCESSWIRE / October 7, 2014 / Theralase Technologies Inc. ("Theralase(R)"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has collaborated with Sigma-Aldrich Corporation's (NASDAQ: SIAL) custom manufacturing services business unit SAFC(R) Commercial , in the manufacture of the Photo Dynamic Compounds ("PDCs"

being developed by Theralase for the destruction of cancer.
SIAL: 136.10 (+0.19), TLT.VN: 0.630 (-0.010)
Theralase Files Voluntary Annual Information Form
ACCESSWIRE - Wed Sep 24, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 24, 2014 / Theralase Technologies Inc. ("Theralase(R)"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has filed a voluntary Annual Information Form ("AIF"

as part of its corporate strategy to become eligible for the registration of a base shelf prospectus as this term is defined in National Instruments 44-101 Short Form Prospectus Distributions and 44-102 Shelf Distributions.
TLT.VN: 0.630 (-0.010)
Theralase Partners with Montreal's JSS Medical Research to Bring Innovative Bladder Cancer Treatment to Market
ACCESSWIRE - Thu Sep 11, 6:01AM CDT
Toronto, Ontario / ACCESSWIRE / September 11, 2014 / To take advantage of the vastly improved business climate in Quebec, Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it is partnering with JSS Medical Research Inc. ("JSS"

, a Montreal based Contract Research Organization ("CRO"

, to consult and provide guidance in the completion of a FDA / Health Canada Phase I/IIa clinical study. The clinical study planned for early 2015 will evaluate the safety and efficacy of Theralase's innovative Photo Dynamic Therapy ("PDT"

platform in the destruction of bladder cancer. Theralase anticipates executing further agreements in the Quebec biotech sector worth several million dollars over the next 12 to 18 months.
TLT.VN: 0.630 (-0.010)
Theralase Launches Multi Wavelength Laser for Cancer Destruction
ACCESSWIRE - Tue Sep 09, 6:04AM CDT
Toronto, Ontario / ACCESSWIRE / September 9, 2014 / Theralase Technologies Inc. ("Theralase"

(TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has successfully launched its TLC-3000 multi wavelength laser system capable of activating its patented and patent pending Photo Dynamic Compounds (PDCs) for the destruction of cancer in an preclinical environment. This is the first commercial system on the market capable of effectively activating a 96 well plate of cancer cells with wavelengths in the visible to Near Infrared (NIR) spectrum using programmable energy levels. Intellectual protection for this system was recently applied for under a pending US patent.
TLT.VN: 0.630 (-0.010)